MDACC Study No:2005-0536 ( NCT No: NCT00299156)
Title:Phase II Study of Oral Clofarabine in Myelodysplastic Syndrome (MDS)
Principal Investigator:Hagop Kantarjian
Treatment Agent:Clofarabine
Study Status:Terminated
Study Description:The goal of this clinical research study is to learn if clofarabine given by
mouth on a weekly schedule can help to control MDS. The safety of clofarabine
given by mouth will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase II
Treatment Agents:Clofarabine
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:5 days
Supported By:N/A
Return Visit:Every 4 to 8 weeks, up to a total of 12 courses of therapy; about 2 to 3 years.
Home Care:Self medicated

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Hagop Kantarjian
For Clinical Trial Enrollment:713-792-7305
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults